Which tests are included in RP testing?

Which tests are included in RP testing?

• A. Fundus photo, Mac OCT, FAF (ONH drusen), ERG, EOG, Goldmann VF, Genetic testing for RPE-65
• B. Fundus photo, Amsler grid, Snellen chart
• C. Only ERG and genetic testing
• D. Slit lamp exam only

Answer: (A)

In retinitis pigmentosa evaluation, you need a broad battery that captures both retinal structure and function, plus genetic information to guide therapy possibilities. Fundus photography documents the characteristic retinal changes, macular OCT shows the integrity of the macula and any cystic changes, and autofluorescence imaging highlights areas of retinal pigment epithelium dysfunction and can reveal features like ONH drusen. Electrodiagnostic tests are crucial: ERG assesses overall retinal function (especially rod versus cone activity), and the EOG gauges retinal pigment epithelium function. Mapping the visual field with Goldmann perimetry reveals the extent of peripheral field loss, which is central to RP progression. Genetic testing, such as testing for an RPE65 mutation, becomes important for identifying eligibility for targeted gene therapies. The other options lack this comprehensive approach; simple acuity or screening tools like the Amsler grid or Snellen chart don’t provide the full picture of RP-specific structural and functional changes, and a slit lamp exam alone doesn’t assess retinal function or detailed structural status.

In retinitis pigmentosa evaluation, you need a broad battery that captures both retinal structure and function, plus genetic information to guide therapy possibilities. Fundus photography documents the characteristic retinal changes, macular OCT shows the integrity of the macula and any cystic changes, and autofluorescence imaging highlights areas of retinal pigment epithelium dysfunction and can reveal features like ONH drusen. Electrodiagnostic tests are crucial: ERG assesses overall retinal function (especially rod versus cone activity), and the EOG gauges retinal pigment epithelium function. Mapping the visual field with Goldmann perimetry reveals the extent of peripheral field loss, which is central to RP progression. Genetic testing, such as testing for an RPE65 mutation, becomes important for identifying eligibility for targeted gene therapies. The other options lack this comprehensive approach; simple acuity or screening tools like the Amsler grid or Snellen chart don’t provide the full picture of RP-specific structural and functional changes, and a slit lamp exam alone doesn’t assess retinal function or detailed structural status.